Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AtriCure, Inc. (ATRC)

AtriCure Q3 revenue rises 15% to $154.5 million; net income $4.1 million

Positive Impact 3 of 5 earnings Written later

AtriCure reported third quarter 2026 revenue of $154.5 million, up 15.0% from a year earlier, and net income of $4.1 million, compared with a net loss of $267 thousand in the same quarter of 2025. The company also projected full year 2026 revenue of approximately $606 million to $610 million and adjusted EBITDA of approximately $91 million to $94 million, which gives shareholders updated figures for the year.

Key points

  • Q3 2026 revenue was $154.5 million, up 15.0%; U.S. revenue rose 17.1% to $128.0 million.
  • Net income was $4.1 million, or $0.08 per diluted share, versus a loss of $0.01 per share a year earlier.
  • Adjusted EBITDA was $26.8 million, up 51% from $17.8 million in Q3 2025.
  • Full year 2026 revenue is now projected at approximately $606 million to $610 million; the filing does not state the prior projection.

The filing

CompanyAtriCure, Inc. (ATRC)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:00 PM ET
Accession number0001323885-26-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.